STOCK TITAN
  1. Home
  2. Sec-filings
  3. ZVSA
  4. [8-K] ZyVersa Therapeutics, Inc. Reports Material Event

[8-K] ZyVersa Therapeutics, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ZVSA logo
ZyVersa Therapeutics Inc

OTC:ZVSA

ZVSA Rankings

#6455 Ranked by Market Cap
N/A Ranked by Dividends

ZVSA Latest News

Aug 14, 2025
ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
Aug 13, 2025
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
Jul 21, 2025
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
Jul 8, 2025
ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
Jul 8, 2025
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis

ZVSA Latest SEC Filings

Jul 18, 2025
[S-1/A] ZyVersa Therapeutics, Inc. Amends IPO Registration Statement
Jul 16, 2025
[Form 4] ZyVersa Therapeutics, Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] ZyVersa Therapeutics, Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] ZyVersa Therapeutics, Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] ZyVersa Therapeutics, Inc. Insider Trading Activity

ZVSA Stock Data

3.12M
8.09M
0.08%
4.34%
7.37%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOMERVILLE